![]() |
市场调查报告书
商品编码
1319152
全球微型生物反应器市场 - 2023-2030 年Global Micro Bioreactor Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
全球微型生物反应器市场规模在 2022 年达到 35 亿美元,预计到 2030 年将达到 72 亿美元,2023-2030 年的复合年增长率为 9.8%。生物技术和生物制药研究的进步、对工艺优化和质量控制的日益关注以及对高通量筛选需求的不断增长是预计在预测期内推动市场发展的部分因素。
微型生物反应器是一种小型生物反应器,用于在受控实验室中培养和观察微生物、细胞或组织。它是传统生物反应器的原子演绎,允许研究人员以较小的规模和较少的体积进行试验。微型生物反应器应用于许多领域,如制药研究、生物技术、生物工程和教育研究。它们可用于细胞培养、干细胞研究、药物开发和操作优化等不同领域。
2022 年 12 月 6 日,德国默克公司收购了 Erbi Biosystems 公司,后者是名为 Breez 的 2 毫升微型生物反应器平台技术的开发商。该公司总部位于美国马萨诸塞州。此次收购于 12 月 1 日完成,通过实现基于细胞的可扩展灌流生物反应器工艺(从 2 毫升到 2,000 升)以及快速的实验室规模工艺开发,加强了总部位于达姆施塔特的制药、化工和生命科学集团在治疗蛋白质领域的上游产品组合。
此外,2020 年 11 月 17 日,贝克曼库尔特生命科学公司签署了一项最终协议,收购位于德国 Baesweiler 的私营微型生物反应器制造商 m2p-labs。m2p-labs 以其变革性的 BioLector 板式微型生物反应器而闻名,该产品支持筛选和生物工艺开发的自动化解决方案。因此,从上述因素来看,市场有望在预测期内得到推动。
2021 年 7 月 19 日,CELLINK 旗下公司 CYTENA Bioprocess Solutions 推出了 S.NEST,这是一种先进的微型生物反应器,可最大限度地促进细胞生长,同时自始至终监控和分析细胞状况。CYTENA Bioprocess Solutions 公司以将创新的生物科学技术与一流的软件开发相结合而著称,该公司开发的新型微型生物反应器颠覆了细胞系开发(CLD)领域。
微型生物反应器在各种下游应用的细胞系开发(CLD)研究中取得了许多突破性进展,而 S.NEST 在增加了实时监控功能后,更是走在了这些进展的前列。它还包括用于往复混合的专利技术、具有独立环境控制功能的培养室、用于实时监测 pH 值和溶解氧的摄像模块、强大的数据分析软件、与 96 孔或 24 孔培养板的兼容性,以及四个培养室可同时进行多达 384 孔的高通量培养。
CLD 研究人员希望简化以前需要数周才能完成的升级和扩展工作流程,S.NEST 独特的悬浮培养方式无疑将为他们带来持续的氧气供应。作为 CYTENA 广泛的单细胞仪器组合的一部分,S.NEST 将为世界各地的实验室提供高效的细胞培养结果。因此,由于上述因素,市场有望在预测期内得到推动。
微型生物反应器经常采用新技术和新设计,没有标准的操作程序。这可能导致数据解释不一致,并使系统或实验室之间难以共享结果。要使微型生物反应器被广泛弃用和接受,就必须制定标准化规程和最佳实践。因此,从上述因素来看,预计在预测期内,市场增长将受到阻碍。
俄罗斯和乌克兰之间的持续冲突有可能影响微型生物反应器市场。冲突可能会阻碍跨境科学合作。新技术(包括微型生物反应器)的叛逃往往是由合作探索努力推动的。但是,如果这些合作因冲突而解体或搁置,可能会减缓受影响地区微型生物反应器的放弃和应用。
在冲突期间,探索的优先顺序可能会发生变化,以应对眼前的挑战和慈善需求。分配给科学研究(包括生物技术和医学)的资金和库房可能会被转用于处理冲突的后果。这种勘探重点的转移可能会对微型生物反应器的需求和总体需求增长产生直接影响。
COVID-19 对全球微型生物反应器市场产生了积极影响。全球对 COVID-19 疫苗的迫切需求导致了大量的研发投资。微型生物反应器在疫苗的快速开发和生产中发挥了关键作用,可实现有效的工艺优化和高产出的疫苗生产。
疫苗研发需求的增加对微型生物反应器的需求产生了积极影响。疫情的爆发凸显了快速和可扩展生物处理技术的重要性。微型生物反应器因其小规模和自动化能力,已被公认为生物制药领域的重要工具。由于对快速工艺开发和生产灵活性的需求,对微型生物反应器和相关技术的需求不断增加。
Global Micro Bioreactor Market reached US$ 3.5 billion in 2022 and is expected to reach US$ 7.2 billion by 2030 growing with a CAGR of 9.8% during the forecast period 2023-2030. The advancements in biotechnology and biopharmaceutical research, growing focus on process optimization and quality control, and rising demand for high-throughput screening are somee of the factors expected to drive the market over the forecast period.
A microbioreactor is a small-scale bioreactor machine used to cultivate and look at microorganisms, cells, or tissue in a controlled laboratory putting. It's an atomic interpretation of the traditional bioreactor that permits researchers to conduct trials on a smaller scale and with less volume. Micro bioreactors are employed in lots of fields, such as pharmaceutical research, biotechnology, bioengineering, and educational research. They are utilized in cell culture, stem cell studies, drug development, and operation optimization, amongst different things.
On December 6, 2022, Germany's Merck acquired Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology known as the Breez. The company is based in the American state of Massachusetts. The acquisition, which closed on December 1, strengthens the Darmstadt-based pharmaceuticals, chemicals, and life science group's upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes from 2 ml to 2,000 L with rapid lab-scale process development.
Additionally, on November 17, 2020, Beckman Coulter Life Sciences signed a definitive agreement to acquire m2p-labs, a privately held, microbioreactor manufacturer based in Baesweiler, Germany. m2p-labs is best known for its transformative BioLector plate-based micro bioreactors, which support automated solutions for screening and bioprocess development. Thus, from the above factors, the market is expected to drive over the forecast period.
On July 19, 2021, CYTENA Bioprocess Solutions, a CELLINK company launched the S.NEST, a state-of-the-art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish. Well-known for combining innovative bioscience technologies with best-in-class software development, CYTENA Bioprocess Solutions has developed its new microbioreactor to disrupt the field of cell line development (CLD).
Micro bioreactors have been instrumental in many research breakthroughs in CLD for a variety of downstream applications, but with the addition of real-time monitoring, the S.NEST is at the forefront of those advances. It also includes patented technology for reciprocating mixing, incubation chambers with individual environmental controls, a camera module for real-time pH and dissolved oxygen monitoring, powerful analytical software to crunch data, compatibility with 96-well or 24-well culture plates, and four chambers for high-throughput culturing of up to 384 wells at once.
CLD researchers looking to streamline upscaling and expansion workflows that previously took weeks to complete will undoubtedly embrace the S.NEST's unique suspension culturing nourished by a continuous supply of oxygen. The S.NEST, as part of CYTENA's extensive portfolio of single-cell instruments, will make highly efficient cell culturing results available to laboratories all over the world. Thus, owing to the above factors, the market is expected to drive over the forecast period.
Micro bioreactors frequently employ novel technologies and designs, and there are no standard operating procedures for them. This can lead to inconsistencies in data interpretation and make it difficult to share results between systems or laboratories. Standardized protocols and best practices must be developed for micro bioreactors to be widely abandoned and accepted. Thus, from the above factors, the market is expected to hamper market growth over the forecast period.
The ongoing conflict between Russia and Ukraine has the potential to impact the micro bioreactor market. The conflict could hinder cross-border scientific collaborations. The defection of new technologies, including micro bioreactors, is frequently driven by cooperative exploration efforts. However, if these collaborations disintegrate or are put on hold due to the conflict, it may slow down the relinquishment and application of micro bioreactors in the affected regions.
Priorities for exploration may shift during times of conflict to address immediate challenges and philanthropic needs. Funding and coffers that would have been allocated to scientific research, including biotechnology and medicine, could be diverted to dealing with the aftermath of the conflict. This shift in exploration priorities may have an immediate impact on demand for micro bioreactors and overall demand growth.
COVID-19 has positively impacted the global micro bioreactor market. The urgent global need for COVID-19 vaccines has resulted in significant investment in research and development. Micro bioreactors have played a critical role in the rapid development and production of vaccines, allowing for effective process optimization and high-output vaccine campaigners.
This increased demand for vaccine development has positively influenced the demand for micro bioreactors. The outbreak highlighted the importance of quick and scalable bioprocessing technologies. Micro bioreactors have been recognized as valuable tools in biopharmaceutical assiduity due to their small-scale and automated capabilities. The demand for micro bioreactors and related technologies has increased as a result of the need for rapid process development and manufacturing inflexibility.
Biopharmaceutical Industry from the Application Segment Account for 32.3% of the Market Share Owing to the Increasing Demand for Biopharmaceutical Products, Flexibility and Scalability, and Technological Advancements in the MicroBioreactors
Micro bioreactors are well-suited for operations in biopharmaceutical exploration, process development, and optimization due to their unique characteristics and advantages. Micro bioreactors allow for the rapid webbing of various cell lines, culture media, and process parameters to optimize bioprocesses. They enable experimenters to estimate multiple experimental conditions at the same time, which speeds up the development of effective and robust bioproduction processes.
Micro bioreactors provide a controlled environment for genetically negotiating cell lines, such as the expression of therapeutic proteins or antibodies. They enable effective evaluation of various gene constructs, selection of high-producing duplicates, and optimization of recombinant protein expression culture conditions.
Micro bioreactors provide a controlled environment for genetically engineering cell lines, including the expression of therapeutic proteins or antibodies. They allow for efficient evaluation of different gene constructs, selection of high-producing clones, and optimization of culture conditions for recombinant protein expression.
For instance, ambr15 is a microscale automated bioreactor system that replicates traditional laboratory-scale bioreactors. The benchtop system is made up of disposable microbioreactor vessels, an automated workstation, and simple software. ambr 15 allows for the automated parallel processing and control of 24 or 48 bioreactor experiments with a single operator. Designed for aseptic operation in a standard laminar airflow biological safety cabinet. When compared to traditional laboratory bioreactors, ambr 15 provides more efficient, consistent, and scalable bioreactor experiments.
Thus, from the above factors, the market segment is expected to hold the largest market share over the forecast period.
North America Accounted for Approximately 39.6% of the Market Share Owing to the Pharmaceutical Companies Wide Presence and a Significant Rise in Micro Bioreactors' Utilization to Produce Novel Ingredients and Drugs for Specific/Uncured Diseases, Strong Investment in Biotechnology and Life Sciences
The North American region's focus on personalized medicine drives the demand for customized cell-based therapies, tissue engineering constructs, and regenerative medicine products. Micro bioreactors play a vital role in the development and production of these personalized therapies by providing a controlled environment for cell culture and process optimization. As the demand for personalized medicine continues to grow, the utilization of micro bioreactors is expected to increase.
The supportive regulatory environment in North America, particularly in the United States, enables faster and more efficient drug development and manufacturing processes. Regulatory agencies like the FDA have shown a willingness to adopt new technologies, including micro bioreactors, which offer benefits in process development, optimization, and cost-effective manufacturing. This favorable regulatory environment reduces barriers to market entry for biopharmaceutical companies utilizing micro bioreactors, thereby driving their adoption.
The major global players in the market include: Sartorius, Stedim, Pall Corporation, M2p-labs, Merck, Applikon Biotechnology, Chemtrix, CerCell, RUAG Space Nyon, PreSens Precision Sensing, and Eppendorf among others.
The global micro bioreactor market report would provide approximately 53 tables, 50 figures, and 195 Pages.
LIST NOT EXHAUSTIVE